GreenLight Biosciences Holdings PBC (GRNA) Stock Price, Quote, News and Overview
NASDAQ:GRNA - Nasdaq - US39536G1058 - Common Stock - Currency: USD
GRNA Quote, Performance and Key Statistics
0.2995
0 (-0.03%)
The current stock price of GRNA is 0.2995 USD. In the past month the price increased by 1.49%. In the past year, price decreased by -85.53%.
GRNA Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 20.17 | 360.78B | ||
| AMGN | AMGEN INC | 15.59 | 165.97B | ||
| GILD | GILEAD SCIENCES INC | 24.19 | 138.97B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1662.14 | 123.83B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.77 | 78.69B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.32B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.50B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.45B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.39B | ||
| NTRA | NATERA INC | N/A | 21.09B | ||
| BIIB | BIOGEN INC | 8.64 | 20.74B | ||
| UTHR | UNITED THERAPEUTICS CORP | 15.85 | 16.11B |
Related stock screener links
About GRNA
Company Profile
GreenLight Biosciences Holdings PBC operates as a biotechnology company, which makes ribonucleic acid (RNA) products for human therapies and agriculture. The company is headquartered in Lexington, Massachusetts and currently employs 262 full-time employees. The company went IPO on 2021-01-14. The firm has a cell-free ribonucleic acid (RNA) production platform for the discovery, development, and commercialization of products to promote healthier plants, foods, and people. The firm's cell-free biomanufacturing platform enables the making of complex biological molecules-nucleic acids, peptides, carbohydrates, and many others using fermentation. Its technology platform provides integrated discovery, design, and development of RNA-based products used in advanced pharma discovery to agriculture and human health. The company has developed two manufacturing processes, one for plant health (dsRNA) and one for human health (mRNA) that both rely on synthesis of RNA from RNA building blocks, enzymes, and deoxyribonucleic acid (DNA) templates. The firm's plant program includes the Colorado Potato Beetle Program-Calantha; Varroa Mite Program, and Powdery Mildew Complex.
Company Info
GreenLight Biosciences Holdings PBC
29 Hartwell Avenue
Lexington MASSACHUSETTS US
Employees: 262
Company Website: https://greenlightbiosciences.com/
Phone: 16176168188.0
GreenLight Biosciences Holdings PBC / GRNA FAQ
What is the stock price of GreenLight Biosciences Holdings PBC today?
The current stock price of GRNA is 0.2995 USD. The price decreased by -0.03% in the last trading session.
What is the ticker symbol for GreenLight Biosciences Holdings PBC stock?
The exchange symbol of GreenLight Biosciences Holdings PBC is GRNA and it is listed on the Nasdaq exchange.
On which exchange is GRNA stock listed?
GRNA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for GreenLight Biosciences Holdings PBC stock?
7 analysts have analysed GRNA and the average price target is 0.46 USD. This implies a price increase of 53.26% is expected in the next year compared to the current price of 0.2995. Check the GreenLight Biosciences Holdings PBC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is GreenLight Biosciences Holdings PBC worth?
GreenLight Biosciences Holdings PBC (GRNA) has a market capitalization of 45.43M USD. This makes GRNA a Nano Cap stock.
How many employees does GreenLight Biosciences Holdings PBC have?
GreenLight Biosciences Holdings PBC (GRNA) currently has 262 employees.
What are the support and resistance levels for GreenLight Biosciences Holdings PBC (GRNA) stock?
GreenLight Biosciences Holdings PBC (GRNA) has a support level at 0.29. Check the full technical report for a detailed analysis of GRNA support and resistance levels.
Is GreenLight Biosciences Holdings PBC (GRNA) expected to grow?
The Revenue of GreenLight Biosciences Holdings PBC (GRNA) is expected to grow by 167.93% in the next year. Check the estimates tab for more information on the GRNA EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy GreenLight Biosciences Holdings PBC (GRNA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of GRNA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of GRNA, evaluating the profitability, health, valuation and growth aspects
- GreenLight Biosciences Holdings PBC (GRNA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- GreenLight Biosciences Holdings PBC (GRNA) Sales and EPS estimates to see what analysts future expectations are.
- GreenLight Biosciences Holdings PBC (GRNA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- GreenLight Biosciences Holdings PBC (GRNA) Insider and Institutional Ownership to learn about the owners and their transactions.
- GreenLight Biosciences Holdings PBC (GRNA) Stock Chart to make your own analysis
- GreenLight Biosciences Holdings PBC (GRNA) Latest news and press-releases to stay up to date.
Does GreenLight Biosciences Holdings PBC (GRNA) stock pay dividends?
GRNA does not pay a dividend.
When does GreenLight Biosciences Holdings PBC (GRNA) report earnings?
GreenLight Biosciences Holdings PBC (GRNA) will report earnings on 2023-08-14, after the market close.
What is the Price/Earnings (PE) ratio of GreenLight Biosciences Holdings PBC (GRNA)?
GreenLight Biosciences Holdings PBC (GRNA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.14).
GRNA Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to GRNA. When comparing the yearly performance of all stocks, GRNA is a bad performer in the overall market: 95.46% of all stocks are doing better.
GRNA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GRNA. GRNA has a bad profitability rating. Also its financial health evaluation is rather negative.
GRNA Financial Highlights
Over the last trailing twelve months GRNA reported a non-GAAP Earnings per Share(EPS) of -1.14. The EPS decreased by -5.79% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0.49 |
GRNA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 46% to GRNA. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 26.28% and a revenue growth 167.93% for GRNA